Business
Erasca Further Strengthens Business Leadership with Two Key Promotions
David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer
About this update from Erasca, Inc.
[{"type":"text","content":"David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer Nik Chetwyn, Ph.D., previously Erasca’s SVP of Operations, has been promoted to Chief Operating Officer SAN DIEGO, May 16, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that David Chacko, M.D., previously chief financial officer (CFO) of Erasca, has been promoted to the dual position of CFO and chief business officer, and Nik Chetwyn, Ph.D., previously senior vice president of operations of Erasca, has been promoted to chief operating officer, with each promotion being effective as of May 15, 2023. “At Erasca, our most important asset is our people, and I am pleased to recognize leaders like David and Nik with promotions that further strengthen our potential for success in building Erasca into a world class organization for the benefit of patients,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “David has been instrumental in building our pipeline by helping: close six in-licensing or acquisition deals, including our four most advanced clinical programs; finance the company through private and public equity offerings that have raised over $700 million; and establish numerous collaborations with industry and academia. I look forward to our next phase of growth as we explore additional strategic opportunities for Erasca. I am also excited to promote Nik in his continued leadership of our operational efforts, covering a broad span of functions, including chemistry, manufacturing, and controls (CMC), information technology, facilities, quality assurance, and portfolio and program leadership. As we progress to becoming a late-stage clinical company, we will continue to leverage Nik’s deep expertise and industry experience in technical drug development.” About David Chacko, M.D. Dr. Chacko is a seasoned leader in strategy, finance, investor relations, business development, and operations. He joined Erasca in 2019 as Chief Business Officer with oversight of our corporate and business development efforts and became Chief Financial Officer in 2020. Prior to joining Era...